Feyza özkan

Dr. Feyza özkan


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Turkiye Klinikleri Journal of Anesthesiology Reanimation
Verified
Journal Article
Open access
PDF file
FÖFeyza özkan
Feyza özkan
ADAkif Demirel
Akif Demirel
KDKemal Demi̇rtaş
Kemal Demi̇rtaş
Amaç: Koronavirüs hastalığı-2019 [coronavirus disease-2019 (COVID-19)] enfeksiyonu sonrası yoğun bakım ünitelerinde tedavi görmüş hastaların nozokomiyal enfeksiyon sıklığı, tipi ve en sık görülen sorumlu etkenlerin araştırılması amaçlanmıştır. Gereç ve Yöntemler: 1 Ekim 2022-1 Ocak 2023 tarihleri arasında Yozgat Şehir Hastanesi 3. Basamak Genel Yoğun Bakım A ve Genel Yoğun Bakım B ünitelerinde takip edilen ve izlemleri sırasında nozokomiyal enfeksiyon gelişen 496 hasta çalışmaya dâhil edildi. Tek merkezli, retrospektif gerçekleştirilen bu tanımlayıcı çalışmada, hasta verileri hastane bilgi sisteminden ve Enfeksiyon Kontrol Komitesi tarafından tutulan kayıtlardan yararlanılarak toplandı. Bulgular: Pandemi dönemi ve sonrası yoğun bakımlarda en sık gördüğümüz etken Acinetobacter baumannii'dir. Pandemi dönemi sırasında bu etken %86,35 oranında görülürken, pandemi sonrası %68,42 oranında görülmüştür. Pandemi dönemi Pseudomonas aeruginos'a %4,55 saptanırken pandemi sonrası bu etken %10,53'e, Escherichia coli pandemi dönemi %4,55 saptanırken pandemi sonrası %15,79 seviyelerine çıkmıştır. Pandemi dönemi Klebsiella pneumoniae etkeni görülürken, pandemi sonrası bu etken yerini Enterococcus faecium'a bırakmıştır. Enfeksiyon bulaşlarında en sık yol ventilatör ilişkili pnömoni, daha az oranlarda ise kateter ilişkili idrar yolu enfeksiyonu ve kan dolaşım enfeksiyonu olarak bildirilmiştir. Sonuç: Çalışmamız, COVID-19 hastalarında ikincil enfeksiyon insidansının daha yüksek ve enfeksiyonda farklı etkenler olduğunu doğrulamaktadır. Bundan dolayı çalışmamız, pandemi sonrası görülme oranları değişen enfeksiyon etkenlerine, izolasyon ve bulaş önlenmelerine yönelik daha dikkatli olunması gerektiğine ve etkin antibiyotik tedavilerinin önemli katkı sağlayacağına inanmaktayız.

23 June 2023 in Medical Journal of Bakırkoy
Verified
Journal Article
Closed access
FÖFeyza özkan
Feyza özkan
AYAhmet Yüksek
Ahmet Yüksek
ADAkif Demirel
Akif Demirel
ÇKÇiğdem Kantekin
Çiğdem Kantekin

1 January 2023 in Cukurova Medical Journal
Verified
Journal Article
Open access
PDF file
FÖFeyza özkan
Feyza özkan
Purpose: The aim of this study was to examine the effect of The transversus abdominis plane (TAP) block after lower abdominal surgery on pain severity and additional analgesic requirement in a pediatric patient group. Materials and Methods: In this retrospective study, 46 ASA I children aged 2-18 years undergoing abdominal surgery were divided into two groups. Group T (n: 20) patients who were under the general anesthesia received ultrasound-guided TAP block with 0.5 mL/kg of 0.25% bupivacaine immediately after the operation. Group O (n: 26) patients were administered intravenous (I.V.) 2 µcg/kg opioid (fentanyl) analgesia after recovery from general anesthesia. The patients were taken to the post-anesthesia care unit (PACU) for recovery and initial pain observation. Patients pain was assessed by using the Visual Analogue Scale (VAS) score within the first 24 hours following surgery. Results: The incidence of the additional analgesic requirement in the TAP block(%15) group was statistically significantly lower than in the I.V. opioid group(%65). There was a difference between the first analgesic requirement and the discharging time according to TAP block administration, but it was statistically insignificant. The VAS scores at 4 hr and 8 hr in the TAP block group were statistically significantly lower than in the IV opioid group(4.VAS:4.90±1,21 5.90±0.85; 8.VAS:4.05±0.76 3.10±0.85). The VAS scores at postoperative 2 hr were decreased in both groups. However, the decrease in the VAS score at 2 hr was greater in the TAP block group. Conclusion: TAP block was superior to IV opioids in reducing additional analgesic requirements in pediatric patients undergoing abdominal surgery. It will contribute further to early discharging a patient as it allows early mobilization.

15 May 2026 in KTO Karatay Üniversitesi Sağlık Bilimleri Dergisi
Verified
Journal Article
Closed access
SZSeda Zor
Seda Zor
FÖFeyza özkan
Feyza özkan
Objectives: This study aimed to evaluate the quality, reliability, and readability of online health information on HIV infection using DISCERN and JAMA BENCHMARK criteria, and to contribute to the improvement of digital health literacy.Materials and Methods: A systematic search was conducted using the keywords "HIV" and "HIV infection" in Google and Yandex search engines. A total of 202 websites from the first 10 pages of both engines were screened. After excluding sites with video content, duplicate content, advertising-focused material, non-Turkish sources, and those available only in PDF/Word format, 93 websites were included in the analysis. Content quality was assessed using the DISCERN instrument and JAMA BENCHMARK criteria; readability was evaluated with the Flesch Reading Ease (FRE) formula.Results: Of the evaluated websites, 47.3% belonged to private hospitals, 26.9% to private individuals, 12.9% to private laboratories, 6.5% to associations, 3.2% to universities, and 1.1% to the Ministry of Health. According to the DISCERN scoring, no website was classified as high or medium quality. Based on JAMA BENCHMARK criteria, 7 sites (7.5%) were rated as high quality (score 3–4) and 34 sites (36.6%) as medium quality (score 2). The average readability score was 63.82 ± 8.51.Conclusion: The majority of online information on HIV infection is of low quality and reliability. The predominance of private health institution websites raises concerns regarding scientific depth and impartiality. Strengthening digital health literacy, improving content quality standards, and directing users to reliable information sources are recommended.

30 June 2022 in Cukurova Medical Journal
Verified
Journal Article
Open access
PDF file
FÖFeyza özkan
Feyza özkan
MDMohammed Deni̇z
Mohammed Deni̇z
COVID-19’da yeni potansiyel tedavi olarak Oxiris hemofiltreli CRRT: Bir vaka serisi

25 March 2026 in Neurological Research
Verified
Journal Article
Closed access
FÖFeyza özkan
Feyza özkan
SZSeda Zor
Seda Zor
MÇMustafa Çakıllı
Mustafa Çakıllı
EYEsra Yılmaz
Esra Yılmaz
EÇErcan Çaçan
Ercan Çaçan
This study evaluated the effects of dexmedetomidine, ketamine, and midazolam on oxidative stress, neuronal injury, and inflammation in a rat traumatic brain injury (TBI) model by measuring malondialdehyde (MDA), S100B, total antioxidant status (TAS), and tumor necrosis factor-alpha (TNF-α) in brain tissue homogenates and serum. Forty adult male rats were randomized into five groups (n = 8): Sham (S), TBI (T), TBI + Dexmedetomidine (D), TBI + Ketamine (K), and TBI + Midazolam (M). TBI was induced using the controlled cortical impact method. Study drugs were administered intraperitoneally 30 minutes after trauma. At 24 hours, blood and brain samples were collected, and homogenates were prepared. MDA, S100B, TAS, and TNF-α were quantified using validated biochemical assays. Relative to Sham, the TBI group showed significantly higher MDA, S100B, and TNF-α and lower TAS in both tissue and serum (p < 0.05). Dexmedetomidine significantly increased TAS and reduced MDA, S100B, and TNF-α in both compartments (p < 0.01). Ketamine produced a pronounced reduction in MDA (p < 0.01), with limited effects on S100B, TAS, and TNF-α. Midazolam yielded partial improvement, mainly lowering TNF-α, without significant changes in the other markers. Among the tested agents, dexmedetomidine provided the most robust protection against oxidative stress, neuronal injury, and inflammation after TBI. Ketamine and midazolam conferred moderate benefits. These data suggest dexmedetomidine may be a more effective option for mitigating secondary brain injury following traumatic insult and support further translational studies to clarify optimal dosing, timing, and mechanisms. Findings align with neuroprotective profiles previously reported for dexmedetomidine in TBI.